Deregulation of the PP2A inhibitor SET shows promising therapeutic implications and determines poor clinical outcome in patients with metastatic colorectal cancer.
about
Protein Phosphatase 2A as a Therapeutic Target in Acute Myeloid LeukemiaThe role of SET/I2PP2A in canine mammary tumors.Overexpression of PP2A inhibitor SET oncoprotein is associated with tumor progression and poor prognosis in human non-small cell lung cancer.SET antagonist enhances the chemosensitivity of non-small cell lung cancer cells by reactivating protein phosphatase 2ACombined targeting of SET and tyrosine kinases provides an effective therapeutic approach in human T-cell acute lymphoblastic leukemia.All roads lead to PP2A: exploiting the therapeutic potential of this phosphatase.Reprogramming the oncogenic response: SET protein as a potential therapeutic target in cancer.Downregulation of microRNA-199b predicts unfavorable prognosis and emerges as a novel therapeutic target which contributes to PP2A inhibition in metastatic colorectal cancer.MYC-dependent recruitment of RUNX1 and GATA2 on the SET oncogene promoter enhances PP2A inactivation in acute myeloid leukemia.Therapeutic Targeting of PP2A.Upregulation of the oncoprotein SET determines poor clinical outcomes in hepatocellular carcinoma and shows therapeutic potential.SET Overexpression is Associated with Worse Recurrence-Free Survival in Patients with Primary Breast Cancer Receiving Adjuvant Tamoxifen Treatment
P2860
Q26752430-C7C9CDA4-08F5-4E33-9F25-B3021CD1D835Q33842870-CEFBA079-4E30-4081-95C4-4193767D0D56Q36020877-4886811F-7D62-4020-B9CA-7FAFFB06DDB7Q36729492-D4E3B0AC-2D24-4B50-88D6-17E3EF7C68C7Q37708933-790D0BA3-87DD-44FB-B3E9-0449B343FBADQ38617799-97D6E1E0-926E-46B3-96C1-4740F625F690Q38678579-FFF283DF-0A5C-4C60-85B6-90655980206BQ41093440-8AA40E17-CA69-47C5-AE36-81F7F5AE29CAQ41553595-BA671DC7-9C5E-4A4C-AC43-23D72DA38E78Q47436859-C0044C7A-28BE-4EE5-9D9C-5B173EA6BAF9Q48064023-759C2195-5311-4EA0-9BAB-8203E6FF382DQ58697376-062215BB-D60F-4A6F-961F-E91471A87F9E
P2860
Deregulation of the PP2A inhibitor SET shows promising therapeutic implications and determines poor clinical outcome in patients with metastatic colorectal cancer.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh
2014年學術文章
@zh-hant
name
Deregulation of the PP2A inhib ...... metastatic colorectal cancer.
@en
type
label
Deregulation of the PP2A inhib ...... metastatic colorectal cancer.
@en
prefLabel
Deregulation of the PP2A inhib ...... metastatic colorectal cancer.
@en
P2093
P1476
Deregulation of the PP2A inhib ...... h metastatic colorectal cancer
@en
P2093
Cristina Caramés
Ion Cristóbal
Jesús García-Foncillas
Juan Madoz-Gúrpide
Rebeca Manso
Sandra Zazo
P304
P356
10.1158/1078-0432.CCR-14-0724
P407
P577
2014-11-11T00:00:00Z